PT  - JOURNAL ARTICLE
AU  - Hasan, Mohammad R.
AU  - Kalikiri, Mahesh K. R.
AU  - Mirza, Faheem
AU  - Sundararaju, Sathyavathi
AU  - Sharma, Anju
AU  - Lorenz, Stephan
AU  - Chemaitelly, Hiam
AU  - El-Kahlout, Reham A.
AU  - Tsui, Kin Ming
AU  - Yassine, Hadi M.
AU  - Coyle, Peter V.
AU  - Khal, Abdullatif Al
AU  - Bertollini, Roberto
AU  - Al Thani, Mohamed H.
AU  - Abu-Raddad, Laith J.
AU  - Tang, Patrick
AU - National Study Group for COVID-19 Epidemiology in Qatar
TI  - Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar
AID  - 10.1101/2021.07.18.21260718
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.18.21260718
4099  - http://medrxiv.org/content/early/2021/07/22/2021.07.18.21260718.short
4100  - http://medrxiv.org/content/early/2021/07/22/2021.07.18.21260718.full
AB  - Complementing whole genome sequencing strategies with high-throughput multiplex RT-qPCR genotyping allows for more comprehensive and real-time tracking of SARS-CoV-2 variants of concern. During the second and third waves of COVID-19 in Qatar, PCR genotyping, combined with Sanger sequencing of un-typeable samples, was employed to describe the epidemiology of the Alpha, Beta and Delta variants. A total of 9792 nasopharyngeal PCR-positive samples collected between April-June 2021 were successfully genotyped, revealing the importation and transmission dynamics of these three variants in Qatar.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Sidra Medicine Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRepresentative SARS-CoV-2 sequence data generated in this study have been deposited in GeneBank with the accession codes MZ571211-MZ571216. https://www.ncbi.nlm.nih.gov